Rafael Amado

2021 - Allogene Therapeutics

In 2021, Rafael Amado earned a total compensation of $9.7M as Chief Medical Officer and Executive Vice President of Research and Development at Allogene Therapeutics, a 265% increase compared to previous year.

Compensation breakdown

Bonus$100,000
Non-Equity Incentive Plan$228,000
Option Awards$1,963,489
Salary$571,591
Stock Awards$6,839,951
Other$11,125
Total$9,714,156

Amado received $6.8M in stock awards, accounting for 70% of the total pay in 2021.

Amado also received $100K in bonus, $228K in non-equity incentive plan, $2M in option awards, $571.6K in salary and $11.1K in other compensation.

Rankings

In 2021, Rafael Amado's compensation ranked 1,086th out of 12,415 executives tracked by ExecPay. In other words, Amado earned more than 91.3% of executives.

ClassificationRankingPercentile
All
1,086
out of 12,415
91st
Division
Manufacturing
373
out of 5,505
93rd
Major group
Chemicals And Allied Products
134
out of 2,375
94th
Industry group
Drugs
113
out of 2,096
95th
Industry
Biological Products, Except Diagnostic Substances
31
out of 449
93rd
Source: SEC filing on April 26, 2022.

Amado's colleagues

We found four more compensation records of executives who worked with Rafael Amado at Allogene Therapeutics in 2021.

2021

David Chang

Allogene Therapeutics

Chief Executive Officer

2021

Alison Moore

Allogene Therapeutics

Chief Technical Officer

2021

Eric Schmidt

Allogene Therapeutics

Chief Financial Officer

2021

Veer Bhavnagri

Allogene Therapeutics

General Counsel

News

You may also like